Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / January 8, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Instil Bio, Inc. ("Instil" or "the Company") (NASDAQ:TIL). Investors who purchased Instil securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/TIL.

Logo, company nameDescription automatically generated

Instil Investigation Details

On January 6, 2026, Instil issued a press release announcing that Axion Bio, Inc. ("Axion"), an Instil subsidiary, "has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. . . . have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (‘Termination Agreement’)." Following this news, Instil’s stock price fell $5.63 per share, or 45.81%, to close at $6.66 per share on January 6, 2026.

What’s Next for Instil Investors?

If you are aware of any facts relating to this investigation or purchased Instil securities, you can assist this investigation by visiting the firm’s site: bgandg.com/TIL. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Instil Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Instil Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire

comtex tracking

COMTEX_471869794/2457/2026-01-08T14:33:26

Scroll to Top